Key Highlights

  • Genus shares rose 3.8% on 5 August 2026 after a July trading update guided FY26 profit moderately ahead of consensus at around £98m.
  • PIC delivered strong growth in Asia and Latin America, offsetting weaker North American results from customer disease challenges.
  • ABS achieved double-digit profit growth despite lower global dairy prices and softer customer demand.
  • A Chinese porcine joint venture with Beijing Capital Agribusiness delivered around £111m of net cash consideration.
  • Projected year-end net leverage stands at a comfortable 0.4 times, supporting the improved balance sheet narrative.

Genus, the FTSE 250 animal-genetics company, rose 3.8% to 2,288p on 5 August 2026 as investors continued to reappraise its recovery prospects. In a July trading update the group said full-year 2026 profit would come in moderately ahead of market expectations, at around £98m of adjusted profit before tax, helped by strong porcine performance in Asia and Latin America and double-digit profit growth in its bovine business. A landmark Chinese joint venture has also strengthened the balance sheet, adding to a more confident narrative around the company's long-term growth in animal breeding and gene editing.

Why the shares moved

Genus gained 84.42p, or 3.83%, to 2,288.42p on 5 August 2026. The move built on a positive trading update issued in July 2026, in which the company guided to full-year results moderately ahead of consensus, and appeared to reflect continued positive sentiment and analyst attention rather than a single fresh announcement on the day. As with many mid-cap shares, several factors can drive a move of this size, and it is best understood as part of a broader re-rating of the recovery story.

Genus had been through a difficult stretch, with animal-disease challenges among North American pork customers and weaker global dairy prices weighing on demand. The July update signalled that the business was turning a corner, with strength elsewhere more than offsetting those headwinds. Confirmation that profit would beat expectations, together with a much-improved balance sheet, gave investors reason to look through the near-term pressures to the group's longer-term potential.

Recent financial and operational performance

Genus supplies elite breeding genetics to livestock producers through two main businesses: PIC, which serves the global pork industry, and ABS, which serves the dairy and beef cattle markets. In its July update the company said it expected full-year 2026 adjusted profit before tax of approximately £98m, moderately ahead of consensus. PIC delivered strong growth in Asia, including China, and in Latin America, offsetting weaker North American results caused by customer disease challenges. ABS achieved double-digit profit growth, supported by its Value Acceleration Programme, though this was tempered by lower global dairy prices and softer customer demand.

The balance sheet has been transformed by the group's Chinese porcine joint venture with Beijing Capital Agribusiness, from which Genus received net cash consideration of around £111m during the fourth quarter, alongside a final £5.6m milestone payment earlier in the year. Strong second-half cash conversion drove a significant increase in free cash flow, leaving projected year-end net leverage at a comfortable level of around 0.4 times. Genus expects to publish its preliminary results in September 2026.

The bull case

The investment case rests on Genus's position as a global leader in animal genetics, a field with high barriers to entry built on decades of proprietary breeding data and science. Demand for more productive, efficient and disease-resilient livestock genetics is underpinned by the long-term need to feed a growing population more sustainably, giving the business a structural growth backdrop that transcends the agricultural cycle.

A particular source of long-term optimism is gene editing, including the group's work on pigs resistant to a costly and widespread porcine disease, which could open a substantial new revenue stream if regulatory approvals progress across key markets. Combined with a strengthened balance sheet and improving cash generation, these growth options give bulls confidence that the recovery has further to run.

There is also an attractive quality to the underlying business model. Genus earns much of its income through royalties and recurring sales of genetic material, giving it a relatively predictable, annuity-like revenue base once its genetics are embedded in a customer's herd. Its vast proprietary databases and long breeding programmes are extremely difficult for competitors to replicate, creating a durable competitive moat. As producers around the world seek to improve the productivity, feed efficiency and disease resilience of their animals, Genus is well placed to capture that demand — a structural growth driver that helps explain why investors are willing to look through cyclical setbacks.

Principal risks

Genus is exposed to the health of global livestock markets, which can be disrupted by animal disease outbreaks — as the North American pork challenges have shown — and by swings in dairy and pork prices that affect customers' willingness to invest in premium genetics. These factors are largely outside the company's control and can be volatile.

The gene-editing opportunity, while promising, depends on regulatory approvals that are uncertain in timing and outcome across different jurisdictions. The group also has significant exposure to China and other emerging markets, bringing political, currency and execution risks. After a strong recovery in the shares, expectations have risen, leaving less margin for disappointment when detailed results are published.

What investors should watch next

The preliminary results due in September 2026 are the next major milestone, offering a full breakdown of PIC and ABS performance, margins and cash flow. Investors should watch the trajectory of North American pork demand as disease pressures ease, the direction of global dairy prices, and progress on the Value Acceleration Programme in the bovine business.

Regulatory developments on gene-edited pigs in major markets are a key longer-term signpost, as is the performance of the Chinese joint venture. Continued progress on cash generation and leverage will indicate the financial health underpinning the group's growth investments.

Outlook

Genus's advance reflects renewed confidence that its recovery is real, with an expected profit beat, a transformed balance sheet and strength in Asia offsetting weaker North American and dairy markets. The longer-term appeal — leadership in animal genetics and the potential of gene editing — gives the story genuine ambition, but disease risk, commodity price swings and regulatory uncertainty remain live concerns. September's results will show whether the improved trading has translated into the earnings the market now expects, and set the tone for how investors judge the pace of the recovery from here.